Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
31
12
2021
received:
20
09
2021
accepted:
31
12
2021
pubmed:
5
1
2022
medline:
15
3
2022
entrez:
4
1
2022
Statut:
ppublish
Résumé
Since 2016, 3 innovative therapies for spinal muscular atrophy (SMA) have changed the face of the disease. Although these therapies often result in remarkable improvements in infants and children, benefits in adults are modest and treatment is not curative. Concerns have been raised about the enormous costs of these medications, the ultimate burden to taxpayers, and the costs to society of withholding treatments and sacrificing or disadvantaging some individuals. Physicians are best positioned to serve our patients by carefully considering the costs, benefits, implications for quality of life (QOL), and the interplay of these factors within the framework of core ethical principles that guide clinical care. ANN NEUROL 2022;91:305-316.
Identifiants
pubmed: 34981567
doi: 10.1002/ana.26299
pmc: PMC9305104
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
305-316Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Orphanet J Rare Dis. 2011 Jun 17;6:42
pubmed: 21682893
J Neurol. 2013 Nov;260(11):2836-43
pubmed: 23989341
Gen Hosp Psychiatry. 2014 Jul-Aug;36(4):392-7
pubmed: 24698057
Muscle Nerve. 2021 Dec;64(6):641-650
pubmed: 34448221
N Engl J Med. 2017 Nov 2;377(18):1723-1732
pubmed: 29091570
Lancet Neurol. 2021 Apr;20(4):284-293
pubmed: 33743238
J Med Chem. 2018 Aug 09;61(15):6501-6517
pubmed: 30044619
Nature. 2011 Oct 05;478(7367):123-6
pubmed: 21979052
Mol Ther. 2016 Feb;24(2):198-201
pubmed: 26906613
Neuromuscul Disord. 2017 May;27(5):428-438
pubmed: 28237437
Nat Biotechnol. 2009 Jan;27(1):59-65
pubmed: 19098898
Ther Clin Risk Manag. 2019 Oct 02;15:1153-1161
pubmed: 31632042
Gene Ther. 2016 Mar;23(3):272-82
pubmed: 26704722
Hum Mol Genet. 2015 Jul 1;24(13):3847-60
pubmed: 25859009
J Neuromuscul Dis. 2019;6(4):453-465
pubmed: 31594243
Neuromuscul Disord. 2019 Nov;29(11):842-856
pubmed: 31704158
J Pathol. 2009 Sep;219(1):52-60
pubmed: 19434631
N Engl J Med. 2021 Mar 11;384(10):915-923
pubmed: 33626251
Lancet Neurol. 2020 Apr;19(4):317-325
pubmed: 32199097
J Pediatr. 2021 Apr;231:265-268
pubmed: 33259859
Hum Mol Genet. 2017 Mar 1;26(5):932-941
pubmed: 28062667
J Neuromuscul Dis. 2021;8(4):553-568
pubmed: 33749617
N Engl J Med. 2017 Nov 2;377(18):1713-1722
pubmed: 29091557
N Engl J Med. 2021 Jul 29;385(5):427-435
pubmed: 34320287
Neurology. 2019 May 21;92(21):e2492-e2506
pubmed: 31019106
Ann Neurol. 2021 Jan;89(1):24-26
pubmed: 33051879
BMJ. 2020 Feb 12;368:m580
pubmed: 32051111
Pharmacoeconomics. 2008;26(9):733-44
pubmed: 18767894
JAMA Neurol. 2021 Jul 1;78(7):834-841
pubmed: 33999158
Muscle Nerve. 2020 Feb;61(2):222-226
pubmed: 31773738
Pediatr Neurol. 2019 Sep;98:39-45
pubmed: 31277975
Neurology. 2019 Oct 1;93(14):640-641
pubmed: 31488615
Cell. 1997 Sep 19;90(6):1023-9
pubmed: 9323130
Hum Mol Genet. 2020 Sep 29;29(16):2674-2683
pubmed: 32644120
Value Health. 2018 May;21(5):547-552
pubmed: 29753351
Orphanet J Rare Dis. 2020 Mar 12;15(1):70
pubmed: 32164772
Hum Mol Genet. 2010 Oct 15;19(20):3895-905
pubmed: 20639395
Hum Mutat. 2000;15(3):228-37
pubmed: 10679938
Ann Neurol. 2005 May;57(5):704-12
pubmed: 15852397
Hum Gene Ther. 2014 Aug;25(8):740-6
pubmed: 24773182
Pediatr Neurol. 2020 Aug;109:12-19
pubmed: 32409122
Mol Ther. 2021 Feb 3;29(2):418-419
pubmed: 33472035
J Neuromuscul Dis. 2020;7(3):257-268
pubmed: 32333595
BMC Neurol. 2017 Apr 4;17(1):68
pubmed: 28376816
Eur J Hum Genet. 2012 Jan;20(1):27-32
pubmed: 21811307
J Cell Biol. 2001 Mar 5;152(5):1107-14
pubmed: 11238465
Bioethics. 2020 Jun;34(5):493-501
pubmed: 31770817
Expert Opin Investig Drugs. 2021 May;30(5):519-527
pubmed: 33749510